Halozyme Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Halozyme Therapeutics

01/11/2024 03:36

* Halozyme Therapeutics Inc  HALO.OQ  reported quarterly
adjusted
earnings of $1.27​​ per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of 75 cents.  The mean expectation of ten analysts
for the quarter was for earnings of 98 cents per share. Wall
Street expected results to range from 93 cents to $1.05 per
share.
    * Revenue rose 34.3% to $290.08 million from a year ago;
analysts
expected $251.06 million. 
    * Halozyme Therapeutics Inc's reported EPS for the quarter
was
$1.05​.
    * The company reported quarterly net income of $137.01
million.
    * Halozyme Therapeutics Inc shares had fallen by 11.6% this
quarter and gained 36.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Halozyme
Therapeutics Inc is 63.00 
This summary was machine generated from LSEG data November 1 at
03:35 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      0.98           1.27           Beat
 Jun. 30 2024      0.76           0.91           Beat
 Mar. 31 2024      0.70           0.79           Beat
 Dec. 31 2023      0.83           0.82           Missed